Winthrop Advisory Group LLC Makes New Investment in HCA Healthcare, Inc. $HCA

Key Points

• Winthrop Advisory Group LLC made a new investment in HCA Healthcare, acquiring 3,797 shares valued at approximately $1,454,000 in the 2nd quarter.
• HCA Healthcare reported $6.84 earnings per share for the last quarter, exceeding expectations and showing a 6.4% year-over-year revenue increase to $18.61 billion.
• The company declared a quarterly dividend of $0.72 per share, resulting in an annualized yield of 0.7% and a dividend payout ratio of 12.11%.

Winthrop Advisory Group LLC bought a new stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 3,797 shares of the company's stock, valued at approximately $1,454,000.

Other large investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of HCA Healthcare by 83.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company's stock worth $829,104,000 after purchasing an additional 1,091,416 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in HCA Healthcare by 49.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company's stock valued at $615,583,000 after buying an additional 587,036 shares in the last quarter. Nuveen LLC purchased a new position in shares of HCA Healthcare during the 1st quarter valued at $569,217,000. Pacer Advisors Inc. grew its position in shares of HCA Healthcare by 6,237.9% during the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company's stock valued at $466,815,000 after purchasing an additional 1,329,618 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of HCA Healthcare by 0.8% during the 1st quarter. Principal Financial Group Inc. now owns 880,663 shares of the company's stock worth $304,313,000 after acquiring an additional 6,888 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Trading Up 0.9%

HCA stock opened at $437.46 on Wednesday. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $439.01. The company has a 50-day moving average price of $401.26 and a 200 day moving average price of $374.10. The stock has a market cap of $102.36 billion, a PE ratio of 18.39, a P/E/G ratio of 1.36 and a beta of 1.40.

HCA Healthcare (NYSE:HCA - Get Free Report) last released its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company had revenue of $18.61 billion during the quarter, compared to analysts' expectations of $18.49 billion. During the same period in the previous year, the company earned $5.50 EPS. The firm's quarterly revenue was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Sell-side analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th were given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.7%. The ex-dividend date was Tuesday, September 16th. HCA Healthcare's dividend payout ratio (DPR) is currently 12.11%.

Analyst Ratings Changes

Several research firms have weighed in on HCA. Barclays boosted their price target on shares of HCA Healthcare from $390.00 to $445.00 and gave the stock an "overweight" rating in a research note on Thursday, September 18th. Weiss Ratings reiterated a "buy (b-)" rating on shares of HCA Healthcare in a research report on Saturday, September 27th. JPMorgan Chase & Co. upped their price objective on shares of HCA Healthcare from $360.00 to $370.00 and gave the stock a "neutral" rating in a report on Monday, August 4th. Wolfe Research downgraded shares of HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research note on Monday, July 28th. Finally, Morgan Stanley lowered their price objective on shares of HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating on the stock in a research report on Monday, July 28th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, HCA Healthcare has a consensus rating of "Moderate Buy" and a consensus price target of $410.83.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the transaction, the executive vice president directly owned 31,503 shares of the company's stock, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is currently owned by insiders.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.